What is William Blair’s Estimate for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for Xenon Pharmaceuticals in a research note issued to investors on Monday, March 17th. William Blair analyst M. Minter anticipates that the biopharmaceutical company will earn ($1.01) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($4.21) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05.

XENE has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $34.94 on Wednesday. The firm has a market cap of $2.67 billion, a P/E ratio of -12.39 and a beta of 1.26. The stock has a 50 day simple moving average of $38.30 and a two-hundred day simple moving average of $39.95. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $46.00.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares in the company, valued at $1,258,340.40. This represents a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.52% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. increased its holdings in shares of Xenon Pharmaceuticals by 3.8% during the third quarter. Advisors Asset Management Inc. now owns 13,592 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 493 shares in the last quarter. Occudo Quantitative Strategies LP increased its holdings in shares of Xenon Pharmaceuticals by 5.8% during the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 630 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company’s stock valued at $2,726,000 after acquiring an additional 720 shares in the last quarter. KBC Group NV increased its holdings in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 780 shares in the last quarter. Finally, HighVista Strategies LLC increased its holdings in shares of Xenon Pharmaceuticals by 1.4% during the third quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company’s stock valued at $2,904,000 after acquiring an additional 1,047 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.